Basilea Pharmaceutica AG
BPMUFOTCHealthcare● Active
$65.10
$-0.00(-0.00%)
Market Cap$805588844
P/E Ratio—
52W High$74
52W Low$47.5
Basilea Pharmaceutica AG (BPMUF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BPMUF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.23B | $0.21B | $0.16B | $0.15B | $0.15B |
| Cost of Revenue | $0.04B | $0.04B | $0.03B | $0.02B | $0.02B |
| Gross Profit | $0.19B | $0.17B | $0.13B | $0.12B | $0.12B |
| Gross Margin %(computed) | 83.09% | 81.45% | 83.00% | 83.35% | 83.75% |
| Operating Expenses | |||||
| R&D Expenses | $0.11B | $0.08B | $0.08B | $0.07B | $0.09B |
| G&A Expenses | $0.00B | $0.03B | $0.03B | $0.03B | $0.03B |
| Total Operating Expenses | $0.14B | $0.11B | $0.11B | $0.03B | $0.03B |
| Operating Income | $0.05B | $0.06B | $0.02B | $0.02B | $0.00B |
| Operating Margin %(computed) | 22.20% | 29.34% | 12.18% | 12.55% | 0.80% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | $0.05B | $0.06B | $0.01B | $0.01B | ($0.01B) |
| Income Tax Expense | $0.01B | ($0.02B) | $0.00B | ($0.00B) | $0.00B |
| Net Income | $0.04B | $0.08B | $0.01B | $0.01B | ($0.01B) |
| Net Margin %(computed) | 17.30% | 37.21% | 6.63% | 8.22% | -4.61% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.29 | $6.42 | $0.86 | $1.02 | $-0.58 |
| Wtd Avg Shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| EBITDA | $0.05B | $0.07B | $0.02B | $0.02B | $0.00B |
| EBITDA Margin %(computed) | 22.20% | 31.81% | 14.74% | 14.69% | 2.40% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CHF · B
Explore more Basilea Pharmaceutica AG data
About Basilea Pharmaceutica AG (BPMUF) Income Statement
Basilea Pharmaceutica AG (BPMUF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BPMUF reported revenue of $0.23B, gross profit of $0.19B (gross margin 83.09%), and net income of $0.04B — a net profit margin of 17.30%.
Frequently asked questions
BPMUF · 4 questionsBasilea Pharmaceutica AG (BPMUF) reported revenue of $0.23B for 2025, up 11.5% year-over-year.
BPMUF revenueBPMUF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09